Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Status:
Not yet recruiting
Trial end date:
2026-04-15
Target enrollment:
Participant gender:
Summary
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK)
inhibitor with high selectivity over other kinases, which is being developed to treat
proteinuric glomerular diseases.
The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and
pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The
first targeted is primary membranous nephropathy.